Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113581
Status:
COMPLETED
Last Update Posted:
2014-02-19
First Post:
2005-06-09
Brief Title:
Safety Study of EMD 72000 in Combination With ECX Epirubicin Cisplatin and Capecitabine in Oesophagogastric Cancer
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
A Phase I Study to Determine the Safety Tolerability Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment EMD 72000 matuzumab for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX epirubicin cisplatin and capecitabine
In addition the study will look at pharmacokinetic how the the body takes up the drug and pharmacodynamic parameters what the drug does in the body
In addition the study will look at pharmacokinetic how the the body takes up the drug and pharmacodynamic parameters what the drug does in the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None